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Abstract
Objective—To summarize the randomized evidence regarding the association between acyclovir 
use and HIV-1 replication as measured by plasma HIV-1 RNA viral load among individuals 
coinfected with herpes simplex virus (HSV)-2.
Design—Meta-analysis of seven randomized trials conducted between 2000 and 2009. Inclusion 
criteria composed of acyclovir or valacyclovir use as prophylaxis among individuals coinfected 
with HIV-1 and HSV-2 who were ineligible for highly active antiretroviral therapy. HIV-1 viral 
load was the outcome.
Methods—Random-effects summarization was used to combine treatment effect estimates. 
Stratified and meta-regression analyses were used to compare estimated treatment effects by 
characteristics of trials and participants.
Results—The summary treatment effect estimate was −0.33 (95% confidence interval: −0.56, 
−0.10, 95% population effects interval: −0.74, 0.08) log10 copies, an approximate halving of 
plasma viral load. However, there was marked heterogeneity (P < 0.001). Older median age, 
valacyclovir, higher compliance, earlier publication, and shorter study length were associated with 
a larger decrease in viral load as compared with their counterparts.
Conclusion—Current evidence suggests a range of favorable effects of acyclovir on plasma 
HIV-1 viral load among persons coinfected with HSV-2.
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Introduction
Recent randomized clinical trials suggest that prophylactic treatment with acyclovir may 
decrease HIV-1 replication among individuals coinfected with herpes simplex virus 
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(HSV)-2 [1–6]. In this context, the effect on HIV-1 replication is measured by a change in 
HIV-1 RNA plasma viral load (henceforth, viral load), which concurrent with antiretroviral 
therapy has been shown to correlate with a delay in disease progression [7]. Although there 
have been trials assessing this relationship between acyclovir use and viral load [1–6,8], to 
our knowledge, no quantitative, systematic review of this literature has been undertaken. 
Below we review and synthesize the published evidence from randomized trials assessing 
the association of acyclovir and viral load with a focus on describing trial characteristics.
Methods
Search strategy and inclusion criteria
We sought published articles that met the following criteria. Studies were randomized, 
placebo-controlled trials of the use of acyclovir as prophylaxis, not as primary use for 
treatment of genital ulcers. Individuals in the trials were coinfected with HIV-1 and HSV-2. 
Participants were not eligible to be on highly active antiretroviral therapy. Finally, trials 
were required to have nonoverlapping participants; when the same participants were part of 
multiple publications, the publication reporting the effect of acyclovir on plasma viral load 
was used. In some cases, trial characteristics from reports not included in the analyses were 
used when the report that met the inclusion criteria did not report those characteristics.
The search terms ‘HIV’ or ‘AIDS’, ‘HSV’ or ‘herpes simplex virus’, and ‘acyclovir’ or 
‘valacyclovir’ were used to identify articles in PubMed, Excerpta Medica database, 
ClinicalTrials.gov, and National Library of Medicine Gateway. The reference lists of found 
articles were searched for additional trials. Searches were conducted in May and June of 
2010.
Statistical analysis
The linear regression coefficient representing the intent-to-treat, mean difference in log10 
HIV-1 plasma viral load at the primary endpoint between treatment and placebo groups and 
95% confidence intervals (CIs) were abstracted from each trial. Standard error estimates for 
each measure were obtained as σj = (aj − bj) = (2 × 1.96), where aj and bj are the reported 
upper and lower 95% CI, respectively, and j = 1 to J indexes the trials.
Covariates abstracted were trial country, trial type (crossover or standard), publication year, 
trial length, average patient age, drug type (acyclovir or valacyclovir) and dose, compliance, 
percentage male, covariate adjustment, treatment protocol for genital ulcers, completion 
rates, and analysis type. Most trials reported median age, though two reported means [3,5]. 
In one trial [2], where age was reported categorically, the average age was estimated by 
taking a weighted average using the midrange of each category. Median compliance was 
measured by pill count in all trials. When compliance was reported only stratified by 
treatment arm [2,4,8], weighted averages were calculated to attain an overall trial summary. 
Baseline viral load should be balanced across treatment groups by randomization, and 
because the outcome measure is not a change score, adjustment for baseline viral load in a 
randomized trial should not alter the point estimate, but should shorten the CI due to a 
reduction in residual variation.
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Overall heterogeneity was assessed by calculating a P value for the Cochran Q statistic, 
which is defined as
where j indexes the trials, Ӯ is the average viral load difference, that is . 
Under the null hypothesis of no heterogeneity, the Qstatistic is distributed as χ2 with J−1 
degrees of freedom. A funnel plot was examined visually for asymmetry (i.e., a plot of 
by yj), and statistically by the method of Egger et al. [9] (i.e., the P value for the test of α0 = 
0 from the linear regression equation , using a rank symmetry test of 
the trial-specific difference estimate and the variance of Begg and Mazumdar [10], as well 
as by the trim and fill method of Duval and Tweedie [11].
Summary measures and 95% CI were calculated by meta-regression using a random 
intercept for trial and restricted maximum likelihood to estimate the among-population 
variance (τ2) [12,13]. This random effects model assumes a distribution of true effects 
among different populations (i.e., different trials). Therefore, we also calculated a 95% 
population effects interval using the among-population variance (τ2); this is the interval 
between which 95% of populations are estimated to have their means. Meta-regression 
models, defined for a covariate X, as yj = (β0 + ν) β1Xj + εj, where ν and εj are independently 
distributed as ν ~ N(0, τ2), and , were also fit with one trial characteristic at a 
time as the independent variable. The small number of trials and clustering of trial 
characteristics prevented the fitting of multivariable meta-regression models. Analyses were 
carried out using SAS version 9.2 (SAS Institute Inc., Cary, North Carolina, USA) and 
STATA version 10.1 (StataCorp LP, College Station, Texas, USA).
Results
Seventeen trials were identified for potential inclusion in the study, all double blinded. Four 
trials overlapped with included trials, three trials were of short-term treatment for genital 
ulcer management, one did not include the outcome under study, one trial was not 
randomized, and in one trial participants were on highly active antiretroviral therapy. In one 
included trial, 8% of participants (n = 41) started antiretroviral therapy during follow-up (C. 
Tanton, personal communication). Seven trials remained for this study and are described in 
Table 1 [1–6,8].
The average age of the trial participants ranged from 28 to 33. Five trials were among 
women only, with one trial among men [6], and one that included both sexes [2]. Four trials 
were conducted in Africa, two in Peru, and one in Thailand. Four trials used acyclovir as the 
trial medication; the other three used its prodrug valacyclovir. All trials treated genital ulcers 
using a short course of high-dose acyclovir or valacyclovir. Completion rates were at or 
above 84% for all trials. All trials reported balanced completion across treatment arms, 
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except one [4] crossover trial. Five of the trials reported an effect measure unadjusted for 
baseline viral load; two reported adjusted estimates. Four of the trials analyzed their data 
using a linear mixed-effects model; three trials used linear regression.
There was no visual appearance of asymmetry in the sparsely populated funnel plot 
(Supplementary Fig 1, http://links.lww.com/QAD/A144). Egger’s and Begg’s test for small-
study effects yielded P values of 0.3 and 0.3, respectively.
Results of stratification by trial characteristics are provided in Table 2. As expected, the 
more bioavailable preparation, valacyclovir, was seen to have a greater association with a 
decrease in viral load. Older median age, higher compliance, and shorter trial length were 
associated with a larger decrease in viral load as compared with their counterparts 
(Supplementary Fig. 2, http://links.lww.com/QAD/A144). Recent publication was 
associated with a lesser decrease in viral load.
The estimated viral load mean difference was −0.33 log10 copies/ml (95% CI: −0.56, −0.10), 
assuming a normal distribution for the random trial effect. The estimated variance of the 
random-effects distribution was 0.0440 (log10 copies/ml)2. Thus, 95% of patient populations 
were estimated to have mean differences in the interval − 0.74−0.08 log10 copies/ml [i.e., 
−0.33 ± 1.96(0.0440)0.5]. From the z-score of −l.58 (= −0.33/0.04400.5), 6% of populations 
were estimated to experience adverse effects on mean viral load (i.e., mean differences 
greater than zero). The Cochran Q statistic was 32.2, with six degrees of freedom (P < 
0.001). This Q statistic measures heterogeneity among the trial-specific effect estimates. 
Therefore, there was notable evidence of heterogeneity. A trim-and-fill analysis, which is 
often used to explore the impact of publication bias, imputed two possibly missing trial 
results, reducing the random effects summary estimate from −0.33 log10 co-to −0.25 log10 
copies/ml.
Discussion
Acyclovir is an inexpensive and readily available drug that is effective at decreasing HSV-2 
shedding, ulcer formation, and HSV-2 transmission in HIV-1-infected and uninfected 
persons [16]. The pooled estimate of −0.33 log10 copies/ml represents a clinically 
meaningful decrease in viral load. In the context of HIV-1 therapy, decreases in plasma viral 
load exhibit a linear relationship with lower risk of AIDS progression and death [17], and 
viral load has subsequently been used as a surrogate marker for these endpoints in clinical 
trials. Associations seen between a larger decrease in viral load with greater compliance and 
shorter trial length in this meta-analysis indicate potential problems for replicating trial 
results in the general population. Further, studies to assess the impact of acyclovir in the 
general HIV-infected population are needed as the observed effect on HIV viral load may be 
mediated by its suppressive effect on HSV, or may be due to direct antiretroviral effects 
[18]. The latter would presumably be independent of HSV infection status. In addition, trials 
with median ages outside the narrow 28–33 year range or that report results stratified by age 
would improve generalizability.
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Caution should be exercised when interpreting the pooled results of this meta-analysis. First, 
meta-analyses are subject to metaconfounding just as observational studies are subject to 
confounding. Second, randomized trials provide internally valid effect estimates assuming 
full compliance and no loss to follow-up. Although most of the loss to follow-up in these 
studies was balanced across treatment arms, there is still potential for selection bias: the 
individuals remaining under study may not be representative of the randomized sample. 
Even internally valid trial comparisons may not generalize to a HIV-infected target 
population that differs in composition from trial populations [19,20], which are often highly 
selective samples. Use of additional antiherpes drugs could impact results. However, in 
these trials a majority of the episodes of herpes that required treatment occurred in the 
placebo group, potentially attenuating the association between acyclovir and viral load. 
Third, results from the trim-and-fill analysis indicate potential publication bias in this 
literature.
Fourth, meta-analyses on aggregate data are vulnerable to ecologic biases as the exposure, 
outcome, and covariates are reported at the group level rather than the individual level. We 
are interested in the individual, biologic effect of acyclovir on HIV-1 plasma viral load, 
rather than the group level effect of acyclovir. For instance, we observed a lesser acyclovir 
association in trials conducted in younger populations. However, given individual data, we 
may see that, within each trial, the acyclovir association is stronger at younger ages. Such a 
finding would be an example of the ecologic fallacy [21].
Random effects estimates assume a distribution of population effects rather than a single 
true effect. The 6% of patient populations estimated to have detrimental association of 
acyclovir with viral load are not consistent with our understanding of possible acyclovir 
mechanisms. Estimating a distribution of effects of acyclovir may not be representative of 
the true effect. Alternatively, the detrimental proportion could be due to chance.
In addition to trials of acyclovir on HIV-1 viral load in plasma, trials have explored 
acyclovir’s effect in genital [3,5], cervical [1,4], cervico-vaginal [8,22], rectal [6], and 
seminal [14] fluids. Generally, a decrease in viral load has been found in these sites 
associated with acyclovir treatment. Although a majority of this literature is among 
participants who were not eligible to be on highly active antiretroviral therapy, the pooled 
estimate from the present meta-analysis is similar to the estimate from the only published 
trial examining HIV-1 plasma viral load among participants on highly active antiretroviral 
therapy (yet poorly controlled with median viral load at randomization of 3.70 log10 copies/
ml), which was −0.41 log10 copies/ml (95% CI: −1.35, 0.53) [23].
This is the first meta-analysis of prophylactic acyclovir and HIV-1 plasma viral load in 
participants coinfected with HSV-2. Although a recent study in HIV-1 and HSV-2 
coinfected persons has shown that despite lowering HIV-1 plasma levels, acyclovir may not 
prevent HIV-1 transmission [2], a separate analysis from that study suggested that acyclovir 
may slow HIV disease progression as measured by a combined outcome of time to CD4 cell 
counts less than 200, antiretroviral therapy initiation, or death [15]. This influential study 
has led some investigators to cautiously propose using acyclovir to slow progression of HIV 
thereby delaying the need for antiretroviral therapy [15,24]. If acyclovir prolongs the time to 
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effective antiretroviral therapy, yet has no effect on reducing transmission, using acyclovir 
in this manner could increase HIV-1 transmission. As antiretroviral therapy becomes 
increasingly affordable and available in the developing world, the modest benefit of 
acyclovir use may become less important. Additional long-term trials, particularly those that 
would assess benefits including time to AIDS and death could help to elucidate the 
mechanism of acyclovir’s effect on HIV-1. Understanding whether the association of 
acyclovir with slowed HIV replication is observed among a broader array of HIV-infected 
populations will help decide how best to use acyclovir in HIV disease management.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Stratified and meta-regression results of randomized control trials of the association between acyclovir and 







(difference of vl difference)
Overall 7 <0.001 −0.33 (−0.56, −0.10)
Study design
  RCT 4 <0.001 −0.34 (−0.92, 0.27) 0.02 (−0.52, 0.56)
  Crossover RCT 3 0.05 −0.33 (−0.57, −0.10) 0
Drug preparation
  Valcyclovir 3 <0.001 −0.46 (−1.25, 0.33) −0.18 (−0.68, 0.31)
  Acyclovir 4 <0.001 −0.26 (−0.59, 0.07) 0
Median age
  >31.05 3 0.02 −0.53 (−1.18, 0.12) −0.30 (−0.68, 0.89)
  ≤31.05 4 0.01 −0.22 (−0.45, 0.00) 0
Compliance
  >96% 3 <0.001 −0.50 (−1.24, 0.24) −0.25 (−0.70, 0.19)
  ≤96% 4 0.009 −0.23 (−0.48, 0.03) 0
Publication year
  2009–2010 3 0.01 −0.19 (−0.66, 0.28) 0.25 (−0.19, 0.69)
  2007–2008 4 <0.001 −0.44 (−0.84, −0.05) 0
Trial length
  >12 weeks 2 0.005 −0.12 (−1.95, 1.71) 0.29 (−0.16, 0.73)
  ≤12 weeks 5 0.001 −0.41 (−0.67, −0.15) 0
Location
  Africa 4 <0.001 −0.34 (−0.92, 0.25) 0.02 (−0.52, 0.56)
  Other 3 0.05 −0.33 (−0.57, −0.10) 0
Adjustment for baseline vl
  Unadjusted 5 0.38 −0.25 (−0.48, −0.03) 0.06 (−0.52, 0.65)
  Adjusted 2 <0.001 −0.36 (−0.75, 0.03) 0
CI, confidence interval; RCT, randomized controlled trial; vl, viral load.
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